Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Of Ibuprofen Interference With Aspirin Cardioprotection

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen 400 mg may interfere with the cardioprotective effect of uncoated low-dose (81 mg) aspirin when they are concomitantly dosed, FDA said in a Sept. 8 science paper

You may also be interested in...



EMA Scrutinizes Ibuprofen’s Cardiovascular Risk Potential

EMA’s Pharmacovigilance Risk Assessment Committee will recommend whether current contraindications, precautions and warnings relating to arterial thrombotic risk of ibuprofen at daily usage of 2,400 mg and up are adequate and whether updates to the product information or other regulatory measures are needed.

EMA Scrutinizes Ibuprofen’s Cardiovascular Risk Potential

EMA’s Pharmacovigilance Risk Assessment Committee will recommend whether current contraindications, precautions and warnings relating to arterial thrombotic risk of ibuprofen at daily usage of 2,400 mg and up are adequate and whether updates to the product information or other regulatory measures are needed.

Naproxen Fares Better Than Ibuprofen In Cardiovascular-Risk Data

Traditional non-selective NSAIDs, with the exception of naproxen, carry similar cardiovascular risk to COX-2 inhibitors, according to results of a study released by the Agency for Healthcare Research & Quality (AHRQ) Sept. 25

Related Content

Topics

UsernamePublicRestriction

Register

PS099757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel